Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clini ...

Arrowhead Pharmaceuticals discovery and translational medicine chief James Hamilton said: “Arrowhead now has two clinical-stage RNAi-based candidates, ARO-ALK7 and ARO-INHBE, for the treatment ...

The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass ...

The RNA interference specialist says its researchers and collaborators have identified mutations in a gene called INHBE that are associated with protection against abdominal obesity and metabolic ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), currently valued at $2.19 billion, has recently presented preclinical data that supports the progression of two RNA interference (RNAi)-based ...

ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to ...

ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to currently ...